<DOC>
	<DOC>NCT00734435</DOC>
	<brief_summary>The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)</brief_summary>
	<brief_title>Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Male or female subjects,1855 years of age Outpatients diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder Body mass index (BMI) between 2235 kg/m2 (inclusive) Negative serum pregnancy test in women of childbearing potential If women of childbearing potential, must be nonlactating and agree to use an acceptable form of contraception, which in all cases, includes one type of barrier method, throughout the study period and for 30 days after discontinuation of study drug Subject requires a change in antipsychotic treatment and olanzapine is deemed by the Investigator to be a reasonable antipsychotic treatment choice No clinically significant abnormality on ECG No clinically significant laboratory abnormality Negative urine drug screen Must be considered reliable and possess a level of understanding that enables the subject to provide written informed consent and to comply with protocol procedures and schedule Must be able to read and understand English Diagnosis of substance dependence within the 6 months prior to randomization diagnosis of substance abuse (except for nicotine and caffeine) within the 3 months prior to randomization Suicidal behavior or ideation within 3 months prior to randomization, or any current suicidal ideation or intent Presence of dementia or other organic brain syndrome Serious or unstable medical illnesses Known, uncorrected narrowangle glaucoma Diagnosis of eating disorder as defined by DSMIV within 6 months prior to randomization Require treatment with any typical or atypical antipsychotic in addition to olanzapine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizophreniform</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>Zyprexa</keyword>
	<keyword>olanzapine</keyword>
</DOC>